M. Duruisseaux

[PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists].

N. Girard, F. Galateau-Sallé, S. Lantuejoul, 2018, Annales de pathologie.

Subtotal Pleurectomy with Intrathoracic Chemo Hyperthermia (HITHOC) for IVa Thymomas: De Novo Versus Recurrent Pleural Disease

N. Girard, P. Rosamel, S. Couraud, 2022, Cancers.

Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.

N. Le Stang, F. Galateau-Sallé, G. Ferretti, 2016, Human pathology.

Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study

B. Besse, K. Bouledrak, V. Westeel, 2022, ESMO open.

37P Sotorasib-induced liver and non-liver toxicity associated with sequential sotorasib following anti-PD(L)1 in KRASG12C mutant lung cancer

C. Mascaux, V. Gounant, A. Lemaitre, 2022, Annals of Oncology.

[PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists].

F. Penault-llorca, A. Mansuet-Lupo, D. Damotte, 2018, Annales de pathologie.